Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences.

Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences, Inc Read more about this drug . Applications have also been submitted to the next other Concerned Member Claims in europe: Austria, France, Germany, Italy, Portugal and Spain. Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Begin GeneticsDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixUsing integrated molecular pathology to manage incidental pancreatic cysts: an interview with Dr Ananya Das’This MAA submission carefully comes after the submission of our NDA to the U.S.